Visterra advances universal flu antibody to cusp of Phase I

Massachusetts-based biotech Visterra is preparing to move its universal influenza therapy into the clinic. Visterra is talking up the engineered antibody as way to both prevent and treat seasonal and pandemic flu infections. News